GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » YoY Rev. per Sh. Growth

TME Pharma NV (XPAR:ALTME) YoY Rev. per Sh. Growth : 0.00% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. TME Pharma NV's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 was 0.00%.

TME Pharma NV's Revenue per Share for the six months ended in Jun. 2024 was €0.00.

TME Pharma NV YoY Rev. per Sh. Growth Historical Data

The historical data trend for TME Pharma NV's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV YoY Rev. per Sh. Growth Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TME Pharma NV YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

TME Pharma NV's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0-0)/ | 0 |
=N/A %

TME Pharma NV's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2024 )
=(Revenue per Share (Q: Jun. 2024 )-Revenue per Share (Q: Jun. 2023 )) / | Revenue per Share (Q: Jun. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
XPAR:POXEL XPAR:ALTAO XPAR:ALTHX XPAR:ALACT XPAR:ALINT XPAR:ALBPS XPAR:GNRO XPAR:ALVIO XPAR:ALMDP XPAR:ALPAT VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
0N6A:Germany
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
Website
https://www.tmepharma.com
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV Headlines

No Headlines